Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights
The second most common breast carcinoma, invasive lobular carcinoma, accounts for approximately 15% of tumors of breast origin. Its incidence has increased in recent times due in part to hormone replacement therapy and improvement in diagnostic modalities. Although believed to arise from the same ce...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/22/5491 |
| _version_ | 1797459854120452096 |
|---|---|
| author | Harsh Batra Jason Aboudi Mouabbi Qingqing Ding Aysegul A. Sahin Maria Gabriela Raso |
| author_facet | Harsh Batra Jason Aboudi Mouabbi Qingqing Ding Aysegul A. Sahin Maria Gabriela Raso |
| author_sort | Harsh Batra |
| collection | DOAJ |
| description | The second most common breast carcinoma, invasive lobular carcinoma, accounts for approximately 15% of tumors of breast origin. Its incidence has increased in recent times due in part to hormone replacement therapy and improvement in diagnostic modalities. Although believed to arise from the same cell type as their ductal counterpart, invasive lobular carcinomas (ILCs) are a distinct entity with different regulating genetic pathways, characteristic histologies, and different biology. The features most unique to lobular carcinomas include loss of E-Cadherin leading to discohesion and formation of a characteristic single file pattern on histology. Because most of these tumors exhibit estrogen receptor positivity and Her2 neu negativity, endocrine therapy has predominated to treat these tumors. However novel treatments like CDK4/6 inhibitors have shown importance and antibody drug conjugates may be instrumental considering newer categories of Her 2 Low breast tumors. In this narrative review, we explore multiple pathological aspects and translational features of this unique entity. In addition, due to advancement in technologies like spatial transcriptomics and other hi-plex technologies, we have tried to enlist upon the characteristics of the tumor microenvironment and the latest associated findings to better understand the new prospective therapeutic options in the current era of personalized treatment. |
| first_indexed | 2024-03-09T16:56:52Z |
| format | Article |
| id | doaj.art-9740ae566d1c46e79a314b02c53026fb |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T16:56:52Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-9740ae566d1c46e79a314b02c53026fb2023-11-24T14:34:45ZengMDPI AGCancers2072-66942023-11-011522549110.3390/cancers15225491Lobular Carcinoma of the Breast: A Comprehensive Review with Translational InsightsHarsh Batra0Jason Aboudi Mouabbi1Qingqing Ding2Aysegul A. Sahin3Maria Gabriela Raso4Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USAThe second most common breast carcinoma, invasive lobular carcinoma, accounts for approximately 15% of tumors of breast origin. Its incidence has increased in recent times due in part to hormone replacement therapy and improvement in diagnostic modalities. Although believed to arise from the same cell type as their ductal counterpart, invasive lobular carcinomas (ILCs) are a distinct entity with different regulating genetic pathways, characteristic histologies, and different biology. The features most unique to lobular carcinomas include loss of E-Cadherin leading to discohesion and formation of a characteristic single file pattern on histology. Because most of these tumors exhibit estrogen receptor positivity and Her2 neu negativity, endocrine therapy has predominated to treat these tumors. However novel treatments like CDK4/6 inhibitors have shown importance and antibody drug conjugates may be instrumental considering newer categories of Her 2 Low breast tumors. In this narrative review, we explore multiple pathological aspects and translational features of this unique entity. In addition, due to advancement in technologies like spatial transcriptomics and other hi-plex technologies, we have tried to enlist upon the characteristics of the tumor microenvironment and the latest associated findings to better understand the new prospective therapeutic options in the current era of personalized treatment.https://www.mdpi.com/2072-6694/15/22/5491ILCbreast carcinomainvasive lobular carcinomatranslational medicinetumor microenvironmenthormone receptor-positive breast cancers |
| spellingShingle | Harsh Batra Jason Aboudi Mouabbi Qingqing Ding Aysegul A. Sahin Maria Gabriela Raso Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights Cancers ILC breast carcinoma invasive lobular carcinoma translational medicine tumor microenvironment hormone receptor-positive breast cancers |
| title | Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights |
| title_full | Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights |
| title_fullStr | Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights |
| title_full_unstemmed | Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights |
| title_short | Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights |
| title_sort | lobular carcinoma of the breast a comprehensive review with translational insights |
| topic | ILC breast carcinoma invasive lobular carcinoma translational medicine tumor microenvironment hormone receptor-positive breast cancers |
| url | https://www.mdpi.com/2072-6694/15/22/5491 |
| work_keys_str_mv | AT harshbatra lobularcarcinomaofthebreastacomprehensivereviewwithtranslationalinsights AT jasonaboudimouabbi lobularcarcinomaofthebreastacomprehensivereviewwithtranslationalinsights AT qingqingding lobularcarcinomaofthebreastacomprehensivereviewwithtranslationalinsights AT aysegulasahin lobularcarcinomaofthebreastacomprehensivereviewwithtranslationalinsights AT mariagabrielaraso lobularcarcinomaofthebreastacomprehensivereviewwithtranslationalinsights |